Publications
70
Citations
815
Est. group size
~3
Recurring co-author estimate
Active years
26
Publishing since 2001
Gwendolen Lorch studies cancer and disease genetics in dogs, with a focus on lung tumors (pulmonary adenocarcinoma) and the gene mutations that drive them, including a well-known cancer-related gene called HER2. This work aims to identify genetic changes that could be targeted by treatments, drawing parallels to similar cancers in humans. Related work also touches on safety assessment of ingredients used in veterinary products.
Publication counts were low and sporadic for most of the past decade, with a sharp, isolated spike in 2023 followed by a return to a low, steady output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions
Veterinary and Comparative Oncology · 2026
- Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines
Veterinary Medicine and Science · 2025
- Author response for "Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines"
2025
- Author response for "Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines"
2025
- Figure S1 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S5 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S3 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Tables S1 to S13 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S2 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S8 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S7 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Data from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Data from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S6 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Figure S4 from Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma
2023
- Veterinary Dermatology×6
- Veterinary Record Case Reports×2
- Communications Biology×1
- Clinical Cancer Research×1
- Journal of Veterinary Internal Medicine×1
- Margaret A. Miller
Medicine · Purdue University West Lafayette
- Maxey L. Wellman
Medicine · The Ohio State University
- William C. Kisseberth
Medicine · The Ohio State University
- Joelle M. Fenger
Medicine · The Ohio State University
- Michael O. Childress
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile